Steady-State Pharmacokinetics and Pharmacodynamics of Benazeprilat in Spontaneously Hypertensive Rats (SHR) and Wistar–Kyoto (WKY) Rats |
| |
Authors: | Sheryl LeRoy Bret Berner |
| |
Affiliation: | (1) Basic Pharmaceutics Research, CIBA-GEIGY Corporation, 444 Saw Mill River Road, Ardsley, New York, 10502 |
| |
Abstract: | The effects of the simultaneous steady-state intravenous infusion of benazeprilat, the active metabolite of benazepril HC1, and angiotensin I (AI) on mean arterial blood pressure were investigated in the conscious, unrestrained spontaneously hypertensive rat (SHR) and its normotensive parent strain, the Wistar–Kyoto (WKY) rat. A competitive inhibition model is applied and the limits of its validity are discussed. Deviations from the model are apparent at high drug infusion rates and may relate to the effect of benazeprilat on the clearance of AI. The strains differ in the amounts of angiotensin converting enzyme (ACE) or responsiveness to angiotensin II (AII), the drug clearances, and either the pharmacology or the distribution of the drug. Since the latter two differences are drug dependent, prediction between strains is rendered difficult. This steady-state approach relates the hypertension in the SHR to the amount of ACE or responsiveness to AII and renal function. |
| |
Keywords: | benazepril benazeprilat pharmacokinetics pharmacodynamics steady state i.v. infusion |
本文献已被 SpringerLink 等数据库收录! |
|